In colon cancer cells fascin1 regulates adherens junction remodeling
The FASEB Journal · 2023
DOI: 10.1096/fj.202201454r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Amin Esmaeilniakooshkghazi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Adherens Junctions, Colonic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, School of Allied Health Sciences, Kitasato University.
Abstract (Originalsprache)
Adherens junctions (AJs) are a defining feature of all epithelial cells. They regulate epithelial tissue architecture and integrity, and their dysregulation is a key step in tumor metastasis. AJ remodeling is crucial for cancer progression, and it plays a key role in tumor cell survival, growth, and dissemination. Few studies have examined AJ remodeling in cancer cells consequently, it remains poorly understood and unleveraged in the treatment of metastatic carcinomas. Fascin1 is an actin‐bundling protein that is absent from the normal epithelium but its expression in colon cancer is linked to metastasis and increased mortality. Here, we provide the molecular mechanism of AJ remodeling in colon cancer cells and identify for the first time, fascin1's function in AJ remodeling. We show that in colon cancer cells fascin1 remodels junctional actin and actomyosin contractility which makes AJs less stable but more dynamic. By remodeling AJs fascin1 drives mechanoactivation of WNT/β‐catenin signaling and generates “collective plasticity” which influences the behavior of cells during cell migration. The impact of mechanical inputs on WNT/β‐catenin activation in cancer cells remains poorly understood. Our findings highlight the role of AJ remodeling and mechanosensitive WNT/β‐catenin signaling in the growth and dissemination of colorectal carcinomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Biochemistry, University of Houston, Houston, Texas, USA.
- Department of Chemical and Bimolecular Engineering, University of Houston, Houston, Texas, USA.
- Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas, USA.
- Gastrointestinal Cancers Programs, Olivia Newton-John Cancer Research Institute, and La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia.
- School of Health Professions, Baylor College of Medicine, Houston, Texas, USA.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- School of Allied Health Sciences, Kitasato University
Zitieren
APA
Esmaeilniakooshkghazi, A., Pham, E., George, S. P., Ahrorov, A., Villagomez, F. R., Byington, M., Mukhopadhyay, S., Patnaik, S., Conrad, J. C., Naik, M., Ravi, S., Tebbutt, N., Mooi, J., Reehorst, C. M., Mariadason, J. M., & Khurana, S. (2023). In colon cancer cells fascin1 regulates adherens junction remodeling. The FASEB Journal. https://doi.org/10.1096/fj.202201454r
Vancouver
Esmaeilniakooshkghazi A, Pham E, George SP, Ahrorov A, Villagomez FR, Byington M, et al. In colon cancer cells fascin1 regulates adherens junction remodeling. The FASEB Journal. 2023. doi:10.1096/fj.202201454r
BibTeX
@article{Esmaeilniakooshkghazi2023,
author = {Esmaeilniakooshkghazi, Amin and Pham, Eric and George, Sudeep P and Ahrorov, Afzal and Villagomez, Fabian R and Byington, Michael and Mukhopadhyay, Srijita and Patnaik, Srinivas and Conrad, Jacinta C and Naik, Monali and Ravi, Saathvika and Tebbutt, Niall and Mooi, Jennifer and Reehorst, Camilla M and Mariadason, John M and Khurana, Seema},
title = {In colon cancer cells fascin1 regulates adherens junction remodeling},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201454r}
}
EUVIMED